Article

Discontinuing Monoclonal Antibodies Targeting CGRP Pathway After One-Year Treatment: An Observational Longitudinal Cohort Study

2021-11-10

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: The monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway revolutionized migraine prevention. However, some drug agencies limited the treatment to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs anti-CGRP on monthly migraine days (MMDs) and disability in high-frequency episodic (HFEM...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 064d582e-2fdc-588b-b640-ed7a17b54196
DOI: 10.21203/rs.3.rs-1047534/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discontinuing Monoclonal Antibodies Targeting CGRP Pathway After One-Year Treatment: An Observational Longitudinal Cohort StudyDOI 10.21203/rs.3.rs-1047534/v1Read

Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalizationSemantic proximity Read

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world DataSemantic proximity Read

Effectiveness of Switching CGRP monoclonal antibodies in non-responder patients in the UAE: A retrospective studySemantic proximity Read

Cgrp Monoclonal Antibodies: Key Lessons from Real World EvidenceSemantic proximity Read

Erenumab in highly therapy-refractory migraine patients First German Real-world evidenceSemantic proximity Read

Unveiling the Efficacy and Safety of Erenumab, a Monoclonal Antibody Targeting Calcitonin Gene-related Peptide (CGRP) Receptor, in Patients with Chronic and Episodic Migraine: A GRADE-assessed Systematic Review and Meta-analysis of Randomized Clinical Trials with Subgroup AnalysisSemantic proximity Read

Efficacy and Safety of CGRP Monoclonal Antibodies for the Prevention of Migraine Compared with Placebo: A Systematic Review and Meta-AnalysisSemantic proximity Read

Safety efficacy and tolerability of the calcitonin gene-related peptide monoclonal antibodies for migraine prevention in a real world settingSemantic proximity Read

Predictors of galcanezumab response in a real-world study of Korean patients with migraineSemantic proximity Read

Efficacy of fremanezumab in refractory chronic migraine patients: Real-world data from the Hull Migraine Clinic, UKSemantic proximity Read

Real-world Evidence Data on the Monoclonal Antibody Erenumab in Migraine Prevention: Perspectives of Treating Physicians in GermanySemantic proximity Read

Psychological Predictors of Negative Treatment Outcome with Erenumab in Chronic Migraine: Data From an Open Label Long-Term Prospective StudySemantic proximity Read